Related Experiment Video
Updated: May 23, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
Optimal fluid control can normalize cardiovascular risk markers and limit left ventricular hypertrophy in thrice
Nestor Velasco1, Paul Chamney, Peter Wabel
1John Stevenson Lynch Renal Unit, NHS Ayrshire & Arran, Kilmarnock, UK.
Insights
Maintaining normal fluid levels in thrice-weekly hemodiafiltration patients is key. Time-averaged fluid overload (TAFO) and cardiac biomarkers can be normal, suggesting bioimpedance monitoring as a practical alternative.
Area of Science:
- Nephrology
- Cardiology
- Biomedical Engineering
Background:
- Chronic fluid overload in hemodialysis patients is linked to left ventricular hypertrophy and elevated cardiac biomarkers, increasing mortality risk.
- While increased dialysis frequency aids fluid management, many patients remain on thrice-weekly treatments.
- Left ventricular hypertrophy (LVH) is a significant concern in chronic kidney disease patients undergoing hemodialysis.
Purpose of the Study:
- To investigate the relationship between time-averaged fluid overload (TAFO), cardiac biomarkers (cTnT, NT-proBNP), and left ventricular mass index (LVMI) in thrice-weekly hemodiafiltration patients.
- To assess if normally hydrated patients on thrice-weekly hemodiafiltration have cardiac biomarker and TAFO levels comparable to the general population.
- To explore bioimpedance spectroscopy as a practical alternative to serum cardiac biomarkers for monitoring fluid status.
Main Methods:
- Studied 30 patients undergoing thrice-weekly hemodiafiltration.
- Measured serum cardiac troponin T (cTnT), N-terminal prohormone brain natriuretic peptide (NT-proBNP), left ventricular mass index (LVMI) via cardiac MRI, and ambulatory blood pressure.
- Quantified time-averaged fluid overload (TAFO) using bioimpedance spectroscopy.
Main Results:
- Twenty-six percent of patients exhibited left ventricular hypertrophy.
- Lower LVMI was significantly associated with TAFO <1 L, NT-proBNP <1200 pg/mL, or cTnT <0.1 ug/L (P < 0.05).
- A significant number of patients achieved normal levels for TAFO, cTnT, and NT-proBNP, suggesting normal hydration is achievable and associated with better cardiac parameters.
Conclusions:
- Normally hydrated thrice-weekly hemodiafiltration patients can exhibit cardiac biomarker and TAFO levels similar to healthy individuals.
- Bioimpedance monitoring of TAFO offers a practical and potentially valuable alternative to traditional serum cardiac biomarkers for assessing fluid status and cardiac risk.
- Effective fluid management is crucial for mitigating cardiac complications in hemodialysis patients.
Abstract:
Increased hemodialysis frequency can make fluid overload easier to treat, although most patients are still treated thrice weekly. Chronic fluid overload is associated with left ventricular hypertrophy and elevated serum cardiac biomarkers, recognized as mortality risk factors. Serum cardiac troponin T (cTnT), N-terminal prohormone brain natriuretic peptide (NT-proBNP), left ventricular mass index by cardiac magnetic imaging, and ambulatory blood pressure was measured in 30 thrice weekly hemodiafiltration patients. Time-averaged fluid overload (TAFO) was quantified by bioimpedance spectroscopy. In the study group, left ventricular hypertrophy was found to be 26% by cardiac magnetic resonance. Ambulatory blood pressure was 130 mmHg (112-151) requiring a low equivalent dose of medication of 0.25 units (0-1). Significantly, lower levels of left ventricular mass index (P < 0.05) were associated in those patients with TAFO <1 L or NT-proBNP <1200 pg/mL or cTnT <0.1 ug/L. In the subgroups, 16 patients had normal cTnT (<0.03 ug/L), 16 patients had NT-proBNP <400 pg/mL, and 20 patients had TAFO <1 L. Nine patients had both cTnT <0.03 ug/L and NT-proBNP <400 pg/mL. Normally hydrated thrice-weekly hemodiafiltration patients can have cardiac biomarker and TAFO levels indistinguishable from the normal healthy population. Obtaining TAFO by bioimpedance monitoring can offer a practical alternative to serum cardiac biomarkers.
Related Concept Videos
Hemodialysis III: Nursing Management
Heart Failure Drugs: Diuretics
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury VI: Nursing Management
Heart Failure VI: Adjunct Therapies
Peritoneal Dialysis III: Nursing Management